Benin Management CORP Sells 100 Shares of Johnson & Johnson (NYSE:JNJ)

Benin Management CORP trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 1.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 7,333 shares of the company’s stock after selling 100 shares during the quarter. Benin Management CORP’s holdings in Johnson & Johnson were worth $1,149,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. 4J Wealth Management LLC increased its stake in shares of Johnson & Johnson by 2.2% in the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock worth $444,000 after purchasing an additional 62 shares in the last quarter. My Personal CFO LLC grew its stake in Johnson & Johnson by 1.4% during the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock valued at $713,000 after acquiring an additional 62 shares in the last quarter. FIDELIS iM LLC grew its stake in Johnson & Johnson by 3.1% during the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock valued at $374,000 after acquiring an additional 64 shares in the last quarter. Clearview Wealth Advisors LLC grew its stake in Johnson & Johnson by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock valued at $685,000 after acquiring an additional 64 shares in the last quarter. Finally, Brookmont Capital Management grew its stake in Johnson & Johnson by 0.4% during the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock valued at $2,328,000 after acquiring an additional 64 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Raymond James boosted their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, March 13th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Finally, Morgan Stanley dropped their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Johnson & Johnson Trading Down 0.9 %

NYSE:JNJ opened at $147.52 on Friday. The company has a fifty day moving average of $157.24 and a 200 day moving average of $155.98. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $355.49 billion, a P/E ratio of 10.68, a P/E/G ratio of 2.50 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. During the same period in the prior year, the business posted $2.35 EPS. The firm’s revenue was down 9.7% compared to the same quarter last year. On average, research analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current year.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.